Author details

Full Name

Stephen L Hauser

Affiliation

ORCID

Career Start Year

1975

Papers

441

H Index

100

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37906326	Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.	J Neurol	2024
38000130	Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.	Mult Scler Relat Disord	2024
35253861	Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans.	Brain	2023
37691530	Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.		2023
36585249	Remote Observational Research for Multiple Sclerosis: A Natural Experiment.		2023
37205595	A Predictive Autoantibody Signature in Multiple Sclerosis.	medRxiv	2023
37461671	Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosis.	medRxiv	2023
36573559	Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis.	Mult Scler	2023
37450172	The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.		2023
36997638	Integration of epigenetic and genetic profiles identifies multiple sclerosis disease-critical cell types and genes.	Commun Biol	2023
36469103	Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis.	Journal of Neurology	2023
36792367	Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.		2023
37354600	Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.	EBioMedicine	2023
37485841	Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.		2023
36657993	CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity.	Neurol Neuroimmunol Neuroinflamm	2023
34878197	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.	Ann Neurol	2022
35461057	Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis.	Multiple Sclerosis and Related Disorders	2022
36038272	Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.	Neurology	2022
35432382	Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.	Frontiers in Immunology	2022
33724638	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.	European Journal of Neurology	2022
33724637	Risk of requiring a walking aid after 6.5Â years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.	European Journal of Neurology	2022
34259588	A smartphone sensor-based digital outcome assessment of multiple sclerosis.	Multiple Sclerosis Journal	2022
35316667	Simultaneous assessment of regional distributions of atrophy across the neuraxis in MS patients.	Neuroimage Clin	2022
35258337	KIR<sup>+</sup>CD8<sup>+</sup> T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19.	Science	2022
35266417	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.	Multiple Sclerosis Journal	2022
35233827	Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS".	Ann Neurol	2022
35229668	Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5â¿¿years.	Multiple Sclerosis Journal	2022
35182500	Multiple sclerosis: two decades of progress.	Lancet Neurology, The	2022
35166689	Building a Precision Medicine Delivery Platform for Clinics: The University of California, San Francisco, BRIDGE Experience.	J Med Internet Res	2022
34475123	Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.	Neurology	2021
34216039	Curing Multiple Sclerosis: How to Know When We're There.	Annals of Neurology	2021
34211458	High Resolution Haplotype Analyses of Classical HLA Genes in Families With Multiple Sclerosis Highlights the Role of HLA-DP Alleles in Disease Susceptibility.	Front Immunol	2021
33503348	Antigen Presentation by B Cells in Multiple Sclerosis.	N Engl J Med	2021
33374005	Cell type-specific transcriptomics identifies neddylation as a novel therapeutic target in multiple sclerosis.	Brain	2021
33202059	Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO.	British Journal of Clinical Pharmacology	2021
33091175	Role of B Cells in Multiple Sclerosis and Related Disorders.	Annals of Neurology	2021
33236967	An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.	Mult Scler	2021
33067847	Retinal INL Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration?	Annals of Neurology	2021
34981055	Human KIR <sup>+</sup> CD8 <sup>+</sup> T cells target pathogenic T cells in Celiac disease and are active in autoimmune diseases and COVID-19.	bioRxiv	2021
34911760	Specific hypomethylation programs underpin B cell activation in early multiple sclerosis.	Proc Natl Acad Sci U S A	2021
34548659	Author Correction: Pan-viral serology implicates enteroviruses in acute flaccid myelitis.	Nat Med	2021
34484932	Electronic Health Record Technology Designed for the Clinical Encounter: MS NeuroShare.	Neurol Clin Pract	2021
33219152	Gut microbiota-specific IgA<sup>+</sup> B cells traffic to the CNS in active multiple sclerosis.	Sci Immunol	2020
32379266	Progress in Multiple Sclerosis Research: An Example of Bedside to Bench.	JAMA - Journal of the American Medical Association	2020
31571307	Intersubject Variability and Normalization Strategies for Spinal Cord Total Cross-Sectional and Gray Matter Areas.	Journal of Neuroimaging	2020
31994814	Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study.	Journal of Neuroimaging	2020
33154077	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS.	AJNR Am J Neuroradiol	2020
32878998	Ataxin-1 regulates B cell function and the severity of autoimmune experimental encephalomyelitis.	Proc Natl Acad Sci U S A	2020
33037294	Two genetic variants explain the association of European ancestry with multiple sclerosis risk in African-Americans.	Sci Rep	2020
32757523	Ofatumumab versus Teriflunomide in Multiple Sclerosis.	N Engl J Med	2020